Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.

MLA

Blaes, Jonas, et al. “Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.” Molecular Cancer Research : MCR, vol. 16, no. 5, May 2018, pp. 767–76. EBSCOhost, https://doi.org/10.1158/1541-7786.MCR-17-0563.

APA

Blaes, J., Thomé, C. M., Pfenning, P.-N., Rübmann, P., Sahm, F., Wick, A., Bunse, T., Schmenger, T., Sykora, J., von Deimling, A., Wiestler, B., Merz, C., Jugold, M., Haberkorn, U., Abdollahi, A., Debus, J., Gieffers, C., Kunz, C., Bendszus, M., … Lemke, D. (2018). Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma. Molecular Cancer Research : MCR, 16(5), 767–776. https://doi.org/10.1158/1541-7786.MCR-17-0563

Chicago

Blaes, Jonas, Carina M Thomé, Philipp-Niclas Pfenning, Petra Rübmann, Felix Sahm, Antje Wick, Theresa Bunse, et al. 2018. “Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.” Molecular Cancer Research : MCR 16 (5): 767–76. doi:10.1158/1541-7786.MCR-17-0563.